Sae-Im Jeong
Ewha Womans University · Medicine
About the Lab
Professor Sae-Im Jeong's research lab specializes in clinical pharmacology and drug disposition, with a strong focus on pharmacokinetics (PK) and pharmacodynamics (PD) of antidiabetic and antiviral agents in diverse patient populations. The lab investigates how renal function and genetic polymorphisms—particularly in drug transporters like P-glycoprotein (P-gp)—influence drug exposure and safety, with translational applications in personalized medicine. Key research directions include optimizing drug therapy in patients with renal impairment, evaluating drug-drug interactions, and applying therapeutic drug monitoring (TDM) in special populations such as pregnant women and those on dialysis. The lab integrates clinical trial data with genetic and physiological insights to improve drug efficacy and safety in metabolic and infectious diseases.
Research Overview
Research Output Trend
Figures are computed from collected data and may differ slightly.
Selected Papers
15Abstract Remdesivir, an antiviral agent for the treatment of coronavirus disease 2019 (COVID‐19), is metabolized intracellularly, with these metabolites eliminated predominantly in urine. Because of a lack of safety and pharmacokinetic (PK) data, remdesivir is not currently recommended for patients with estimated glomerular filtration rate less than 30 ml/min/1.73 m 2 and those on hemodialysis. This study evaluated the PKs of remdesivir and its metabolite, GS‐441524, in patients with COVID‐19 wh
P-glycoprotein (P-gp) is a transporter that plays an excretory role in epithelial cells. It is encoded by <i>ABCB1</i>, and single nucleotide polymorphisms (SNPs) in this gene can affect systemic drug exposure. Dapagliflozin and sitagliptin, used in type 2 diabetes treatment, are P-gp substrates. Here, we aimed to investigate whether <i>ABCB1</i> polymorphisms affect dapagliflozin and sitagliptin pharmacokinetics (PK) in healthy Korean subjects. The study population consisted of 100 healthy Kore
Abstract Aims To explore the effect of renal function on the pharmacokinetic (PK) and pharmacodynamic (PD) profile and safety of enavogliflozin, a selective sodium‐glucose cotransporter 2 (SGLT2) inhibitor, in patients with type 2 diabetes mellitus (T2DM). Methods An open‐label, two‐part clinical trial was conducted in T2DM patients, stratified by renal function: Group 1, normal renal function; Group 2, mild renal impairment (RI); Group 3, moderate RI; and Group 4, severe RI. In Part A, Groups 2
AIMS: DWP16001, a novel sodium-glucose cotransporter 2 inhibitor, is under clinical development for the treatment of type 2 diabetes mellitus. This study aimed to explore the pharmacokinetics (PK) and pharmacodynamics interaction of DWP16001 with gemigliptin and metformin. METHODS: A randomized, open-label, 2-sequence, 2-period crossover study was conducted in 34 healthy male subjects. All subjects received a single oral dose of DWP16001 2 mg with and without gemigliptin and metformin (8 days of
Fetal tachycardia (FT) is a rare disorder and is associated with significant mortality of fetus. Digoxin is one of the antiarrhythmic agents used to treat FT via transplacental therapy. In this report, we describe a therapeutic drug monitoring (TDM) case of digoxin during the treatment of FT. A 40-year-old woman, gravida 2 para 1, hospitalized to control FT as the fetal heart rate (FHR) showed over 200 bpm on ultrasonography at 29 weeks of gestation. She did not have any medical or medication hi
ClinicalTrials.gov Identifier: NCT05182684.
ClinicalTrials.gov Identifier: NCT06147908.
Research Areas
Dive deeper into Sae-Im Jeong's research on Nubint
Open this lab's papers in the app to read with AI, summarize, and cite in your writing.